Deutsche Bank Research maintained its 'Buy' rating on Novartis AG with a price target of 140 Swiss francs, according to a note published Tuesday by analyst Emmanuel Papadakis. The assessment was based on weekly prescription data and reflects the bank’s constructive view on the Swiss pharmaceutical company.
The upgrade follows a period of heightened volatility across global equity markets, where blue-chip valuations have faced pressure despite ongoing geopolitical risks and rising interest rates. Deutsche Bank’s research team highlighted concerns over thin summer liquidity and historically elevated valuations as key risk factors for investors.
Technical indicators have also signaled potential caution, with several record highs failing to gain follow-through momentum. The bank’s report did not specify a publication date for the underlying study beyond its initial release on Aug. 25, 2026, at 08:10 CET.
